Patients were stratified by baseline serum potassium level into mild or moderate hyperkalemia groups and received @ of @ randomized starting doses of patiromer ( @ g -LSB- n = @ -RSB- , @ g -LSB- n = @ -RSB- , or @ g -LSB- n = @ -RSB- twice daily -LSB- mild hyperkalemia -RSB- or @ g -LSB- n = @ -RSB- , @ g -LSB- n = @ -RSB- , or @ g -LSB- n = @ -RSB- twice daily -LSB- moderate hyperkalemia -RSB- ) .